Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal […]
This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury […]
Genialis and Inventia Life Sciences agreed to work together to improve how new treatments for pancreatic cancer are tested and matched to the patients most likely to benefit. The companies will combine Genialis’ AI-powered patient […]
FairJourney Bio (FJBio) selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions to replace spreadsheet-based records and manual reporting processes across its international operations. FJBio is a global antibody discovery […]
Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not the only—beneficiaries when the companies announced what they said were the first-ever positive Phase III results for their mRNA-based […]
The days of biotech businesses and institutions limiting their research and commercial activity to top clusters like Boston/Cambridge, MA, and the San Francisco Bay Area are passing, as the life sciences expand their horizons to […]
Axiom Biosciences, a privately held developer of regenerative therapies and targeted biologics that rebranded last month from Cytonus Therapeutics, made headlines around the world when it announced plans to go public through an initial public […]
Insilico Medicine (Hong Kong Exchange: 3696), an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first […]
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, the companies said, in a deal that would expand the buyer’s rare disease portfolio beyond its anchor indication of cystic fibrosis (CF), by […]
Cytiva has completed an expansion of its Logan, UT, facility that effectively doubles its liquid media production capacity, a project designed to support supply chain continuity for customers relying on the company for their cell […]
Insilico Medicine will partner with SK Biopharmaceuticals to discover new artificial intelligence (AI)-based drug candidates for disorders affecting the neuroimmune area of the central nervous system (CNS), through a collaboration that could generate up to […]
SAN DIEGO—California’s three life sciences clusters all lost jobs last year, yet the industry remains a major engine of innovation and economic growth, according to a report released by the state’s largest life sciences organization […]
SAN DIEGO — AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, the companies said today, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance […]
Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates through a collaboration that could generate up to $510 million in milestone payments for the artificial intelligence-based drug design company whose […]
10x Genomics has acquired Proteintech Genomics for an undisclosed price, the companies said, in a deal driven by the buyer’s commitment to expanding its multiomics presence—in this case, by strategically expanding its proteomics capabilities. The […]
Once labeled the “disease of kings” because of its association with consuming rich foods and alcohol, gout has emerged as a royal pain to a growing number of people. A 2024 study showed the prevalence […]
Some of the forces that shape biopharma cluster development are constants year after year, such as the emergence of startups from university and research institute labs to develop new treatments, thanks to ideas backed by […]
10x Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24 multiomics platform, Teton chemistry, and related services infringe on four university-owned patents exclusively licensed by the genomics and sequencing tools giant—while Element […]
The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha) as the first gene therapy designed to restore a neurosensory function to normal levels. Otarmeni is an adeno-associated virus vector-based gene therapy indicated […]
UCB has agreed to acquire Candid Therapeutics for up to $2.2 billion, the companies said, in a deal to expand the buyer’s presence in T-cell engager (TCE) antibodies designed for immunology indications by adding Candid’s […]
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion, the companies said, in a deal designed to bolster the buyer’s portfolio of marketed endocrinology and rare disease therapies. “This transaction will advance Neurocrine’s […]
Eli Lilly (NYSE: LLY) won the approval it sought when the FDA authorized the company’s oral obesity drug Foundayo (orforglipron), but the pharma giant’s post-approval stock bounce was short-lived. Lilly shares rose 4% from $919.77 […]
The past year marked a proverbial inflection point for organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments or animal models. The FDA in October approved the first-ever investigational new […]
Avidity Biosciences found an eager buyer for its neuroscience pipeline when Novartis shelled out approximately $12 billion to acquire the RNA drug developer, in a deal completed late last month. But when it came to […]
Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs starting with two of Takeda’s therapeutic areas through a multi-year tech and discovery collaboration […]
For months, executives in biopharma and other life sciences have been expressing optimism that in 2026, the industry will emerge from its post-COVID-19 doldrums. They have cited positive trends ranging from the rebound of the […]
With a trio of partnership announcements this month, 10x Genomics has signaled it is looking beyond its traditional focus on research tools for academic, government, and industry customers, by expanding into clinical diagnostics through collaborations […]
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last spring. […]
Before the federal government shut down for 43 days while President Donald Trump and members of Congress wrangled over whether a stopgap spending bill should extend Obamacare tax credits set to expire December 31, the […]
Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a Phase III drug designed to prevent influenza […]
Copyright © 2026 Biotech Networks, LLC
